[go: up one dir, main page]

MA26984A1 - Derives d'ethers utiles comme inhibiteurs d'isozymes pde4 - Google Patents

Derives d'ethers utiles comme inhibiteurs d'isozymes pde4

Info

Publication number
MA26984A1
MA26984A1 MA27242A MA27242A MA26984A1 MA 26984 A1 MA26984 A1 MA 26984A1 MA 27242 A MA27242 A MA 27242A MA 27242 A MA27242 A MA 27242A MA 26984 A1 MA26984 A1 MA 26984A1
Authority
MA
Morocco
Prior art keywords
alkyl
represent
group
groups
inhibitors
Prior art date
Application number
MA27242A
Other languages
English (en)
Inventor
Robert James Chambers
Thomas Victor Magee
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26984A1 publication Critical patent/MA26984A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 31 JANVIER 2001 60/265,304 Voir en annexe le titre de l'invention et le texte de l'abrégé TITRE Dérivés d'éthers utiles comme inhibiteurs d'isozymes PDE4 Composés utiles comme inhibiteurs de PDE4 dans le traitement de maladies régulées par l'activation et la dégranulation des cellules eosinophiles, notamment de l'asthme, de la bronchite chronique et d'une maladie pulmonaire obstructrive chronique, de formule (I) dans laquelle j est égal à 0 ou 1 ; sous réserve que, lorsque j est égal à 0, n soit égal à 2 ; k est égal à 0 ou 1 ; m est égal à 1, 2 ou 3 ; n est égal à 1 ou 2 ; W1 et w2 représentent des groupes -O- ; -S(=O)t-, dans lequel t est égal à 0, 1 ou 2 ; ou -N(R3)- ; Y représente un groupe =C(R1a)-, ou -[N->(O)k]- dans lequel k est égal à 0 ou 1 ; R1a représente un groupe -H ; -F ; -Cl ; -CN ; -NO2 ; -alkyle en C1 à C4 ; -alcynyle en C2 à C4 ; -fluor-alkyle en C1 à C4 ; -fluoralkoxy en C1 à C3 ; -OR16 ou -C(=O)NR22aR22b ; RA et RB représentent des groupes -H ; -F, -CF3 ; -alkyle en C1 à C4 ; -cycloalkyle en C3 à C7 ; phényle ou benzyle substitué avec 0 à 3 substituants R10 ; ou bien RA et RB sont pris conjointement pour former un groupement spiro de formule (Ia) dans laquelle r et s ont des valeurs de 0 à 4, sous réserve que la somme r + s soit supérieure ou égale à 1 mais non supérieure à 5 ; et XA représente un groupe -CH2-, -CHF, -CF2, -NR15-, -O- ou -S(=O)t-, dans lequel t est égal à 0 ou 1 ; Rc et RD sont identiques à RA et RB, sauf qu'un d'entre eux doit représenter -H ; R1 et R2 représentent des groupes -H, -F, -Cl, -CN, -NO2, alkyle en C1 à C4, alcynyle en C2 à C4, fluoralkyle en C1 à C3, -OR16 ou -C(=O)NR22aR22b ; R3 représente -H, -alkyle en C1 à C3, phényle, benzyle ou -OR16 ; R4, R5 et R6, D, J1 et J2 répondent aux définitions figurant dans la présente demande.
MA27242A 2001-01-31 2003-07-21 Derives d'ethers utiles comme inhibiteurs d'isozymes pde4 MA26984A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26530401P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
MA26984A1 true MA26984A1 (fr) 2004-12-20

Family

ID=23009905

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27242A MA26984A1 (fr) 2001-01-31 2003-07-21 Derives d'ethers utiles comme inhibiteurs d'isozymes pde4

Country Status (34)

Country Link
US (3) US6828333B2 (fr)
EP (1) EP1373258B1 (fr)
JP (1) JP2004518689A (fr)
KR (1) KR20030070150A (fr)
CN (1) CN1527830A (fr)
AP (1) AP2002002415A0 (fr)
AR (1) AR032522A1 (fr)
AT (1) ATE305467T1 (fr)
BG (1) BG107960A (fr)
BR (1) BR0116845A (fr)
CA (1) CA2436544A1 (fr)
CR (1) CR7043A (fr)
CZ (1) CZ20031902A3 (fr)
DE (1) DE60113731T2 (fr)
EA (1) EA200300652A1 (fr)
EE (1) EE200300361A (fr)
ES (1) ES2248231T3 (fr)
GT (1) GT200200012A (fr)
HU (1) HUP0302891A2 (fr)
IL (1) IL156460A0 (fr)
IS (1) IS6847A (fr)
MA (1) MA26984A1 (fr)
MX (1) MXPA03006885A (fr)
NO (1) NO20033399L (fr)
NZ (1) NZ526531A (fr)
OA (1) OA12541A (fr)
PA (1) PA8537901A1 (fr)
PE (1) PE20020846A1 (fr)
PL (1) PL364910A1 (fr)
SK (1) SK8942003A3 (fr)
SV (1) SV2003000861A (fr)
TN (1) TNSN03051A1 (fr)
WO (1) WO2002060896A1 (fr)
ZA (1) ZA200304893B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200300652A1 (ru) * 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Эфирные производные, полезные в качестве ингибиторов изозимов pde4
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6777432B1 (en) * 2001-09-04 2004-08-17 Darwin Molecular Corporation Pharmaceutical uses and synthesis of nicotinamides
EA008108B1 (ru) * 2001-09-19 2007-04-27 Алтана Фарма Аг Комбинация нспвлс и ингибитора pde-4
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
WO2004067006A1 (fr) * 2003-01-27 2004-08-12 Pharmacia Corporation Combinaison d'un inhibiteur de la pde iv et d'un antagoniste du tnf-alpha
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317471D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
JP2007504201A (ja) * 2003-09-05 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト 真性糖尿病の治療のためのｐｄｅ４阻害剤の使用
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
JP2007533726A (ja) 2004-04-22 2007-11-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
CA2570047C (fr) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxybenzonitriles utilises comme modulateurs d'androgenes
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
WO2006094942A1 (fr) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast pour le traitement du diabète sucré
WO2006111495A1 (fr) * 2005-04-19 2006-10-26 Nycomed Gmbh Utilisation de roflumilast pour traiter l'hypertension pulmonaire
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
CA2625153A1 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
EP1971345A2 (fr) * 2005-12-20 2008-09-24 Tika Läkemedel AB Méthode et système d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8569229B2 (en) * 2008-02-07 2013-10-29 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
AU2009279667A1 (en) 2008-08-05 2010-02-11 Invasc Therapeutic, Inc. Novel methylenedioxy phenolic compounds and their use to treat disease
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
EP2433124B1 (fr) * 2009-05-19 2017-03-01 Vivia Biotech S.L. Procédés permettant de fournir des essais de médicaments personnalisés ex vivo pour des tumeurs hématologiques
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8697691B2 (en) * 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
CN108299418A (zh) * 2017-09-14 2018-07-20 刘双伟 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法
HUE067466T2 (hu) * 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물
CN114907315B (zh) * 2022-05-17 2023-09-12 重庆医科大学 Selitrectinib中间体的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
DE69130605T2 (de) 1991-02-27 1999-05-20 Lacer, S.A., Barcelona Antihypertensive N-(alpha-substituiertes Pyridyl)-carbonyldipeptide
US5602438A (en) * 1991-02-28 1997-02-11 Robert Bosch Gmbh Roll commutator for electric motors and dynamos, and method of manufacturing it
DE4200323A1 (de) 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
ATE275951T1 (de) 1993-06-18 2004-10-15 Smithkline Beecham Corp Verfahren zur identifizierung eines pde iv hemmers
JP3406689B2 (ja) 1994-03-15 2003-05-12 株式会社大塚製薬工場 ナフチリジン及びピリドピラジン誘導体
US5618027A (en) * 1994-07-20 1997-04-08 Nevrekar; Venkatesh R. Gate valve
WO1996019990A1 (fr) 1994-12-23 1996-07-04 Smithkline Beecham Corporation Monomeres 4,4-(disubstitues)cyclohexan-1-carboxylate et composes correspondants
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
EP0796619A1 (fr) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Utilisation de (+)-alpha-(2,3-diméthoxyphényle)-1-(2-(4-fluorophényle)éthyle)-4-pipéridineméthanol pour le traitement des troubles dépressifs et bipolaires
FR2754178B1 (fr) * 1996-10-04 2002-08-23 Adir Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5922557A (en) 1997-01-09 1999-07-13 Merck & Co., Inc. System for stably expressing a high-affinity camp phosphodiesterase and use thereof
CN1254335A (zh) 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
UA67753C2 (uk) 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
MA24682A1 (fr) 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
SK10342002A3 (sk) * 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4
EA200300652A1 (ru) * 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Эфирные производные, полезные в качестве ингибиторов изозимов pde4

Also Published As

Publication number Publication date
EP1373258B1 (fr) 2005-09-28
WO2002060896A1 (fr) 2002-08-08
PL364910A1 (en) 2004-12-27
MXPA03006885A (es) 2003-11-13
US6828333B2 (en) 2004-12-07
US20070161681A1 (en) 2007-07-12
PE20020846A1 (es) 2002-09-21
IL156460A0 (en) 2004-01-04
SK8942003A3 (en) 2004-10-05
ES2248231T3 (es) 2006-03-16
EA200300652A1 (ru) 2003-12-25
CN1527830A (zh) 2004-09-08
NO20033399L (no) 2003-09-25
ATE305467T1 (de) 2005-10-15
NZ526531A (en) 2005-02-25
US20050049258A1 (en) 2005-03-03
CA2436544A1 (fr) 2002-08-08
DE60113731D1 (de) 2006-02-09
TNSN03051A1 (fr) 2005-12-23
SV2003000861A (es) 2003-01-13
US7183293B2 (en) 2007-02-27
OA12541A (en) 2006-06-05
IS6847A (is) 2003-06-16
CZ20031902A3 (cs) 2004-07-14
GT200200012A (es) 2002-09-02
DE60113731T2 (de) 2006-06-29
PA8537901A1 (es) 2002-10-31
EE200300361A (et) 2003-12-15
CR7043A (es) 2003-11-25
BG107960A (en) 2004-10-29
JP2004518689A (ja) 2004-06-24
EP1373258A1 (fr) 2004-01-02
BR0116845A (pt) 2004-02-25
NO20033399D0 (no) 2003-07-30
ZA200304893B (en) 2004-06-24
AR032522A1 (es) 2003-11-12
HUP0302891A2 (hu) 2003-12-29
AU2002222428A2 (fr) 2002-08-12
KR20030070150A (ko) 2003-08-27
AP2002002415A0 (en) 2002-03-31
US20030027845A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
MA26984A1 (fr) Derives d'ethers utiles comme inhibiteurs d'isozymes pde4
MA26983A1 (fr) Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4
MA26985A1 (fr) Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4
MA29255B1 (fr) Derives de pyrazole destines a inhiber les kinases dependantes des cyclines (cdk) et les glycogene synthases kinases (gsk)
MA33562B1 (fr) Mélanges de pesticides méso-ioniques
TW200946522A (en) BACE inhibitors
CO4600636A1 (es) Derivados de indazol
MA34450B1 (fr) Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
MA27713A1 (fr) Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases
DE602004024093D1 (de) 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
HUP0204271A2 (en) Pyrimidine carboxamides useful as inhibitors of pde4 isozymes, pharmaceutical compositions containing them and their use
JP2011530596A (ja) ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
WO2007071632A3 (fr) Derives de pyridinyl-quinazoline et leur utilisation medicale
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
MEP11508A (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
PE20081160A1 (es) Arilsulfonil-pirrolidinas como inhibidores 5-ht6
MA31738B1 (fr) Triazolo {1,5-a}quinoléines utilises comme ligands du recepteur a3 de l'adenosine
ATE480239T1 (de) Angiogeneseinhibitoren
ATE464296T1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor-modulatoren
NO20072444L (no) Karbamatforbindelser for anvendelse i behandling av neurodegenerative forstyrrelser
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
EA200700103A1 (ru) НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1